Vergote I - Search Results

1

The role of inhibins B and antimüllerian hormone for diagnosis and follow-up of granulosa cell tumors.

Geerts I, Vergote I, Neven P, Billen J. Geerts I, et al. Among authors: vergote i. Int J Gynecol Cancer. 2009 Jul;19(5):847-55. doi: 10.1111/IGC.0b013e3181a702d1. Int J Gynecol Cancer. 2009. PMID: 19574772

2

Randomized trial comparing cisplatin with radioactive phosphorus or whole-abdomen irradiation as adjuvant treatment of ovarian cancer.

Vergote IB, Vergote-De Vos LN, Abeler VM, Aas M, Lindegaard MW, Kjørstad KE, Tropé CG. Vergote IB, et al. Among authors: vergote de vos ln. Cancer. 1992 Feb 1;69(3):741-9. doi: 10.1002/1097-0142(19920201)69:3<741::aid-cncr2820690322>3.0.co;2-g. Cancer. 1992. PMID: 1730124 Clinical Trial.

3

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

Assikis VJ, Neven P, Jordan VC, Vergote I. Assikis VJ, et al. Among authors: vergote i. Eur J Cancer. 1996 Aug;32A(9):1464-76. doi: 10.1016/0959-8049(96)00184-0. Eur J Cancer. 1996. PMID: 8911103 Review.

4

Should tamoxifen users be screened for endometrial lesions?

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Lancet. 1998 Jan 17;351(9097):155-7. doi: 10.1016/S0140-6736(05)78216-7. Lancet. 1998. PMID: 9449866 No abstract available.

5

Controversies regarding tamoxifen and uterine carcinoma.

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14. doi: 10.1097/00001703-199802000-00003. Curr Opin Obstet Gynecol. 1998. PMID: 9484623 Review.

6

Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.

Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, Deprest J, Neven P, Moerman P, Bullerdiek J, Van den Berghe H. Dal Cin P, et al. Among authors: vergote i. Cancer Res. 1998 Jun 1;58(11):2278-81. Cancer Res. 1998. PMID: 9622058

7

Tamoxifen, screening and new oestrogen receptor modulators.

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Best Pract Res Clin Obstet Gynaecol. 2001 Jun;15(3):365-80. doi: 10.1053/beog.2001.0182. Best Pract Res Clin Obstet Gynaecol. 2001. PMID: 11476559 Review.

8

Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary.

Makar AP, Kaern J, Kristensen GB, Vergote I, Børmer OP, Tropé CG. Makar AP, et al. Among authors: vergote i. Int J Gynecol Cancer. 1993 Sep;3(5):299-303. doi: 10.1046/j.1525-1438.1993.03050299.x. Int J Gynecol Cancer. 1993. PMID: 11578361

9

Endodermal sinus tumor of the vulva: successfully treated with high-dose chemotherapy.

Traen K, Logghe H, Maertens J, Mattelaere C, Moerman P, Vergote I. Traen K, et al. Among authors: vergote i. Int J Gynecol Cancer. 2004 Sep-Oct;14(5):998-1003. doi: 10.1111/j.1048-891X.2004.14540.x. Int J Gynecol Cancer. 2004. PMID: 15361214

10

Immunohistochemical expression of CD10 antigen in uterine adenosarcoma.

Amant F, Steenkiste E, Schurmans K, Verbist L, Abeler VM, Tulunay G, de Jonge E, Massuger L, Moerman P, Vergote I. Amant F, et al. Among authors: vergote i. Int J Gynecol Cancer. 2004 Nov-Dec;14(6):1118-21. doi: 10.1111/j.1048-891X.2004.14610.x. Int J Gynecol Cancer. 2004. PMID: 15571618

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

888 results

Search Page

Filters